- Home
- TSHA vs ECPG Comparison
TSHA vs ECPG Comparison
Compare TSHA & ECPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSHA
- ECPG
- Stock Information
- Founded
- TSHA 2019
- ECPG 1998
- Country
- TSHA United States
- ECPG United States
- Employees
- TSHA N/A
- ECPG N/A
- Industry
- TSHA Biotechnology: Pharmaceutical Preparations
- ECPG Finance Companies
- Sector
- TSHA Health Care
- ECPG Finance
- Exchange
- TSHA Nasdaq
- ECPG Nasdaq
- Market Cap
- TSHA 728.4M
- ECPG 806.1M
- IPO Year
- TSHA 2020
- ECPG 1999
- Fundamental
- Price
- TSHA $2.38
- ECPG $40.07
- Analyst Decision
- TSHA Strong Buy
- ECPG Strong Buy
- Analyst Count
- TSHA 5
- ECPG 3
- Target Price
- TSHA $8.20
- ECPG $62.67
- AVG Volume (30 Days)
- TSHA 3.7M
- ECPG 255.0K
- Earning Date
- TSHA 08-11-2025
- ECPG 08-06-2025
- Dividend Yield
- TSHA N/A
- ECPG N/A
- EPS Growth
- TSHA N/A
- ECPG N/A
- EPS
- TSHA N/A
- ECPG N/A
- Revenue
- TSHA $7,224,000.00
- ECPG $1,380,750,000.00
- Revenue This Year
- TSHA N/A
- ECPG $21.70
- Revenue Next Year
- TSHA N/A
- ECPG $8.86
- P/E Ratio
- TSHA N/A
- ECPG N/A
- Revenue Growth
- TSHA N/A
- ECPG 11.49
- 52 Week Low
- TSHA $1.05
- ECPG $26.45
- 52 Week High
- TSHA $3.31
- ECPG $51.77
- Technical
- Relative Strength Index (RSI)
- TSHA 41.03
- ECPG 50.09
- Support Level
- TSHA $2.29
- ECPG $38.69
- Resistance Level
- TSHA $2.48
- ECPG $39.86
- Average True Range (ATR)
- TSHA 0.17
- ECPG 0.99
- MACD
- TSHA -0.05
- ECPG -0.08
- Stochastic Oscillator
- TSHA 9.21
- ECPG 30.96
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
About ECPG Encore Capital Group Inc
Encore Capital Group Inc is an international specialty finance company. It provides debt recovery solutions for consumers and property owners across a broad range of financial assets. The company purchases portfolios of defaulted consumer receivables at deep discounts to face value and manages them by working with individuals as the consumers repay their obligations and work toward financial recovery. Encore has only a reportable segment portfolio purchasing and recovery.